Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00682786 · ClinicalTrials.gov registry record · Phase 2
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT00682786 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 135 participants.
The verdict
NCT00682786, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical controls.
Interventions
- DRUG Irinotecan
- RADIATION Radiation
- DRUG 5FU
- PROCEDURE Surgery of resectable lesions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2002-10 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00682786
The ClinicalTrials.gov registry entry for NCT00682786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Irinotecan is the first listed.
NCT00682786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00682786 about?
NCT00682786 is a clinical study titled "Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma". Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical controls.
What is the current status of trial NCT00682786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2002-10. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00682786?
The interventions under investigation include: Irinotecan (DRUG), Radiation (RADIATION), 5FU (DRUG), Surgery of resectable lesions (PROCEDURE).
Who is sponsoring clinical trial NCT00682786?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.